Photocure appoints Dennis Camporeale as new chief financial officer
Photocure ASA has named Dennis Camporeale CFO effective October 26, 2026, Reuters and TradingView reported, citing the company's press release.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Norway's Photocure ASA, which develops diagnostics for urological cancers, has appointed Dennis Camporeale as its chief financial officer. He takes up the role on October 26, 2026. Reuters and TradingView reported the change, with TradingView citing the company's press release. According to the company, Camporeale has 25 years of experience as a senior healthcare investment banker and corporate finance leader. He previously led the Life Science Tools and Diagnostics practice at Canaccord Genuity and helped Ally Financial's predecessor GMAC become a standalone public company, including its US IPO. CEO Dan Schneider said: "Dennis's experience across medtech, diagnostics and life sciences investment banking brings a valuable combination of industry insight, financial expertise and strategic perspective."
why it matters
For markets this is a routine corporate update with little likely effect on Photocure's shares. A CFO change mainly matters to investors who track the company's reporting, growth and the development of its product portfolio.
tags
instruments
sources
- Photocure ASA Says New CFO Appointed — Reuters, 22 October 2026 at 15:06 UTC
- Photocure ASA - New CFO Appointed — TradingView, 22 October 2026 at 16:06 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗